文献速递血脂与心血管预防肺血管病与心包/心肌炎

PCSK9抑制剂对静脉血栓栓塞风险的影响

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
PubMed 文献 · Circulation · 2020-03-29

FOURIER试验事后分析显示,依洛尤单抗组静脉血栓栓塞(VTE)风险有降低趋势(HR 0.71,95%CI 0.50-1.00;P=0.05),1年后风险降低46%。FOURIER与ODYSSEY OUTCOMES的荟萃分析显示PCSK9抑制剂使VTE相对风险降低31%(HR 0.69,95%CI 0.53-0.90;P=0.007)。基线Lp(a)较高者依洛尤单抗降低Lp(a) 33 nmol/L并降低VTE风险48%,多基因风险评分可识别VTE高风险患者。

要点

  • PCSK9抑制剂可显著降低静脉血栓栓塞风险,荟萃分析相对风险降低31%。
  • 依洛尤单抗对VTE的获益在治疗1年后显现,1年内未见显著效果。
  • 基线Lp(a)较高者从依洛尤单抗获得的VTE风险降低更显著。

核心结论

  • PCSK9抑制可显著降低静脉血栓栓塞风险,Lp(a)降低可能是介导该效应的重要机制。

研究设计与样本

  • FOURIER试验的事后分析,评估依洛尤单抗对VTE事件(深静脉血栓或肺栓塞)风险的影响。
  • 将FOURIER与ODYSSEY OUTCOMES数据合并进行荟萃分析,评估PCSK9抑制对VTE风险的类效应。
  • 分析FOURIER基线血脂以探讨依洛尤单抗降低VTE的潜在机制。
  • 在FOURIER中进行探索性遗传分析,判断VTE多基因风险评分能否识别从依洛尤单抗获益最大的高危患者。

主要发现

  • FOURIER中依洛尤单抗组VTE的风险比(HR)为0.71(95%CI 0.50-1.00;P=0.05)。
  • FOURIER中第1年无显著效果(HR 0.96,95%CI 0.57-1.62),1年后风险降低46%(HR 0.54,95%CI 0.33-0.88;P=0.014)。
  • FOURIER与ODYSSEY OUTCOMES荟萃分析显示PCSK9抑制使VTE相对风险降低31%(HR 0.69,95%CI 0.53-0.90;P=0.007)。
  • 基线低密度脂蛋白胆固醇水平与VTE风险降低幅度无关。
  • 基线Lp(a)较高者依洛尤单抗降低Lp(a) 33 nmol/L、VTE风险降低48%(HR 0.52,95%CI 0.30-0.89;P=0.017);基线Lp(a)较低者仅降低Lp(a) 7 nmol/L且对VTE风险无影响(HR交互P=0.087;绝对风险降低异质性P=0.037);基线Lp(a)作为连续变量与VTE风险降低幅度存在显著交互(P交互=0.04)。

临床怎么用

  • 对于接受PCSK9抑制剂治疗的患者,尤其基线Lp(a)较高或VTE多基因风险评分较高者,可能同时获得VTE风险降低的额外获益。

局限性

  • FOURIER分析为事后分析,VTE并非预设主要终点。
  • VTE风险降低在治疗1年后才显现,短期获益不明确。
  • Lp(a)与VTE风险降低的交互作用部分P值接近0.05,需谨慎解读。
  • 多基因风险评分分析为探索性,尚未在临床常规中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of VTE, explore potential mechanisms, and examine the efficacy in subgroups with clinically and genetically defined risk. METHODS: We performed a post hoc analysis of the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) testing whether evolocumab reduces the risk of VTE events (deep venous thrombosis or pulmonary embolism). Data from FOURIER and ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab) were then combined in a meta-analysis to assess the class effect of PCSK9 inhibition on the risk of VTE. We also analyzed baseline lipids in FOURIER to investigate potential mechanisms explaining the reduction in VTE with evolocumab. Last, an exploratory genetic analysis was performed in FOURIER to determine whether a VTE polygenic risk score could identify high-risk patients who would derive the greatest VTE reduction from evolocumab. RESULTS: In FOURIER, the hazard ratio (HR) for VTE with evolocumab was 0.71 (95% CI, 0.50-1.00; P=0.05), with no effect in the 1st year (HR, 0.96 [95% CI, 0.57-1.62]) but a 46% reduction (HR, 0.54 [95% CI, 0.33-0.88]; P=0.014) beyond 1 year. A meta-analysis of FOURIER and ODYSSEY OUTCOMES demonstrated a 31% relative risk reduction in VTE with PCSK9 inhibition (HR, 0.69 [95% CI, 0.53-0.90]; P=0.007). There was no relation between baseline low-density lipoprotein cholesterol levels and magnitude of VTE risk reduction. In contrast, in patients with higher baseline lipoprotein(a) (Lp[a]) levels, evolocumab reduced Lp(a) by 33 nmol/L and risk of VTE by 48% (HR, 0.52 [95% CI, 0.30-0.89]; P=0.017), whereas, in patients with lower baseline Lp(a) levels, evolocumab reduced Lp(a) by only 7 nmol/L and had no effect on VTE risk (Pinteraction 0.087 for HR; Pheterogeneity 0.037 for absolute risk reduction). Modeled as a continuous variable, there was a significant interaction between baseline Lp(a) concentration and magnitude of VTE risk reduction (Pinteraction=0.04). A polygenic risk score identified patients who were at >2-fold increased risk for VTE and who derived greater relative (Pinteraction=0.04) and absolute VTE reduction (Pheterogeneity=0.009) in comparison with those without high genetic risk. CONCLUSIONS: PCSK9 inhibition significantly reduces the risk of VTE. Lp(a) reduction may be an important mediator of this effect, a finding of particular interest given the ongoing development of potent Lp(a) inhibitors.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Marston NA, Gurmu Y, Melloni GEM, et al. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020. PMID: 32223429. doi:10.1161/CIRCULATIONAHA.120.046397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。